Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

PW, the people should and are clamoring for the best therapeutic for the times, Zyesami/Aviptadil

In our current roles as U.S. surgeon general and chief science officer for the U.S. Covid-19 Response, we have helped coordinate the United States’ fight against the coronavirus. Until recently, we’ve had the funding to make sure that there will be enough vaccines and antiviral drugs to meet the nation’s needs. Now, for the first time, we cannot order enough vaccines to provide boosters for all Americans if a fourth dose is deemed necessary in the fall. If we need variant-specific vaccines, we will not have the funds to secure them, deliver them or administer them.

https://www.nytimes.com/2022/03/29/opinion/covid-funding-america.html

The Republicans noted in the letter that Fauci actually touted ZYESAMI as a promising treatment for COVID-19 almost a year ago, but refused to make it widely available until clinical trials were completed.

“The drug remains largely unavailable, and we are told FDA refuses to review the data of NRx’s EUA until the National Institute of Health (NIH) completes clinical trials of ZYESAMI later this year,” they wrote.

Two years into a pandemic and with a death toll exceeding a reported 900,000 Americans, it is unacceptable that the FDA and NIAID are needlessly delaying a treatment for late-stage COVID-19 with a remarkable track record of success. This bureaucratic dragging of your feet appears in stark contrast to the expedited review of other treatments like remdesivir, Molnupiravir, Paxlovid and the COVID-19 vaccines. The FDA’s disparate review processes for different treatments that appears to favor large manufacturers is troubling.

In an interview with Horowitz, Dr. Flavio Cadegiani, a Brazilian endocrinologist who has treated 2,400 COVID patients without losing a single one, explained how the drug fights the virus.

“Aviptadil is a drug that mimics vasoactive intestinal polypeptide (VIP), however, with prolonged effects, compared to the endogenous (produced by the body) VIP,” he said. “VIP and aviptadil act in a type of lung cell called alveolar type II (AT-2), that, although representing just as few as 5% of the cells in the lungs, are largely responsible for oxygen transfer and inhibition of dysfunctional hyper inflammatory reaction and cytokine storm, through the inhibition of the activity of one of the main triggers of these reactions, called NMDA-induced caspase-3.”

Dr. Cadegiani noted that “to date, there is no other molecule capable of working at late stage against COVID-19, and at the same not causing immunosuppression.”

https://amgreatness.com/2022/03/09/in-letter-to-fda-and-niaid-ron-johnson-demands-to-know-why-promising-late-stage-covid-drug-was-never-approved/